ArticleTherapeutic advances in gastroenterology2018

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Viktoria Bergqvist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.